PRECISION BIOSCIENCES INC

DTIL is the ticker symbol for Precision BioSciences, Inc., a clinical-stage biotechnology company. The stock represents equity ownership in the company and trades on the Nasdaq under the DTIL ticker. As a clinical-stage firm, its value is closely tied to the progress of its gene editing and cell therapy programs. For the latest price and company updates, refer to the real-time data displayed on this page.

Precision BioSciences is a clinical-stage gene editing company, meaning its future depends heavily on clinical trial outcomes and regulatory decisions. The company may have limited revenue and could rely on partnerships or financing to fund operations. Understanding its pipeline, cash position, and collaboration agreements is essential. Also, consider the inherent risks of biotechnology stocks, including scientific, regulatory, and competitive challenges.

DTIL's stock price fluctuates due to company-specific news such as clinical trial data, partnership announcements, or financing activities. Broader market conditions, including interest rates and biotech sector sentiment, also play a role. Additionally, changes in analyst opinions or shifts in the competitive landscape for gene editing can impact investor perception and drive price movements. For current price changes, see the latest data on this page.

Evaluating DTIL requires a different approach than established companies, as clinical-stage biotechs often lack earnings. Investors may look at cash burn rate, pipeline potential, and partnership value. Metrics like enterprise value or price-to-book can offer some perspective, but future cash flows from successful therapies are key. Since DTIL may not have a meaningful P/E ratio, focus on the company's scientific progress and financial runway.

DTIL shares can be purchased through a brokerage account, either online or via a full-service broker. You'll need to place a buy order specifying the number of shares and order type, such as market or limit. The stock trades on the Nasdaq under the ticker DTIL. Ensure your brokerage supports Nasdaq trading and consider any commissions or fees. Fractional shares may be available depending on your broker.

Key risks include clinical trial failures, regulatory delays, and intense competition in gene editing. As a clinical-stage company, DTIL may need additional capital, potentially diluting shareholders. Intellectual property disputes or manufacturing challenges could also arise. Furthermore, reliance on partnerships and the possibility of negative study results can significantly impact the stock. Investors should review the company's SEC filings for detailed risk factors.